View Report Details`
Global Hemophilia Market Report -------------------------------------------------2012
View Report Details Executive Summary With an ever changing technological environment and an unstable economic scenario, many scientific studies are being conducted which are leading to the discovery of new coagulation factors, proteins and plasma concentrates used for treating chronic diseases and medical conditions. The market for hemophilia products has shown continuous growth in the past years growing at a CAGR of around 8.96% during 2006-11 and is projected to expand steadily in the years to come. The occurrence rate of bleeding disorders such as hemophilia is increasing, calling for an increased usage of blood plasma products. The male population of the world is rising and males are the ones who are worst affected by hemophilia as they carry only one X chromosome. Females are only the carriers of this disease. Furthermore, the increasing expenditure is also responsible for higher utilization of recombinant and plasma derived coagulation factors. The existing treatments for hemophilia treatment comprise of blood plasma derivatives and recombinant factors. The leading players in the hemophilia treatment market include: Baxter, Grifols, Pfizer and Novo Nordisk, among others, competing mainly on the basis of product pricing and performance, supply of the products, and continuous offering of new and innovative protein and blood plasma derivatives. Apart from this, the presence of several players operating at domestic level, emergence of new players, and agreements with government agencies, academic and research institutions make the therapeutic landscape of hemophilia market fiercely competitive. The key trends in the hemophilia treatment market are the increasing inclination towards prophylaxis, limiting the use of central venous access device for prophylactic treatment, development of long-acting Factor VIII and IX, deep penetration of rFVIII products within the emerging markets. The recent developments in the respective field include gene therapy for treating hemophilia B, half life extension of the recombinant coagulation factors, development of 4-factor PCC for reversal of vitamin K antagonist anticoagulant therapy along with recent approval of ADVATE in China apart from other clinical trials on run. The major factors driving the growth of the industry are the increasing number of new patients registering themselves for treatment at the hospitals and other healthcare institutions, growing male population, rising expenditure on healthcare globally, and the increased life expectancy for hemophilia patients. Although this industry has been witnessing an aggressive growth with latest technological advancements, still there are factors like antibody neutralization and lack of diagnostic facilities leading to improper or late detection of the disease, which are posing acute challenges in front of every other person falling within the realm of this therapeutic field. The report provides an analysis of the global hemophilia treatment market. It also discusses the major trends, growth drivers and potential markets. The report presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Growth of Hemophilia market over last five years Number of Patients by Hemophilia Type (2011) Depending upon the coagulation factor deficiency, are different types of hemophilia:
there
- Type …..: Dominant genus all over the world, which occurs due to the inability to produce clotting factor …………..occurring in one in …………………..births. ………………………………….. - Type ………: Caused by the lack of clotting factor ……… and is known to affect a large ………………. …………………………………………………………… ………………….. - Hemophilia with ……..: Certain patients develop inhibitors against coagulation factor ……………... ………………………………………coagulation factor ……….., a drug manufactured by ………….. Existing Treatments for hemophilia are: Global Hemophilia Treatment Market Revenues (2006-2011)
- Blood Plasma derivatives:……………….. - Recombinant factors: …………………….. The global hemophilia treatment market revenues have been moving on an aggressive growth path,……………….. ………………….
US$ Billion
The global hemophilia market growth of about …………% was observed in 2011 over ………………………………….. ………………………………………
2006 2007 2008 2009 2010 2011
Latest technological advancements driving Market growth The recombinant FVIII market showed a rising trend due to its wide acceptance over………………………………………………... ………………………….………………growth of roughly………… ………..%over a period…………………US$..... ……………billion ………………….. to US$....... …..billion in 2011.
Global Recombinant FVIII Market Revenues (2005-2011) )
US$ Billion
The global treatment market for hemophilia B was worth US$......... billion in 2010. As a whole, ………………….……..% ………………………………………………………………………….. ………………………………………………….. Out of the total hemophilia treatment market size, somewhere around US$....billion of sales …………..…………………………… …witnessed an increase of ……% from US$.... billion in ………………………………………………………………………… ……………. 2005
2006
2007
2008
2009
2010
2011
Annual Global Sales of NovoSeven (2007-2011)
Global Recombinant FIX Market Size (2006-2011)
US$ Billion
US$ Billion
)
2006
2007
2008
2009
2010
2011
2007
2008
2009
2010
2011
Presence of several market players and Government agencies making market competitive…………. Global Male Population (2005-2014F)
2014F
2013F
2012F
2011
2010
2009
Over 22 years
2008
18-21 years
2007
13-17 years
2006
12 years & under
2005
%
Billion
Use of Prophylaxis in Different Age Brackets (2011)
•
Males predominantly suffer with hemophilia as they have only single X chromosome in the pair of somatic chromosomes. The global male population ……………………………………………………………………………………………………………………..
•
The ongoing trends in the hemophilia market are …………………………………………………………………………………………….
•
Industry developments include gene therapy development for treating hemophilia B, development of ……….PCC for reversal of vitamin K …………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………..
•
The major factors driving the industrial growth are rising male population, ………, increasing ……………………………………… ………………………………………………………………………………………………………..
•
The key players of the industry are …………………………………………………………………………………………………..
•
The global hemophilia market is forecasted to be US$........billion for the year 2012 as compared to US$........billion in 2011, registering a minute increase of roughly….%. …………………………………………………………………………………………………. ……………………………………………………………………………….
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
View Report Details Table of Contents
List of Graphs & Tables
1. Hemophilia: An Overview
List of Graphs
2. Market Overview 2.1 Global Hemophilia Market Market Value No. of Patients
Number of Patients by Hemophilia Type (2010) Global Hemophilia Treatment Market Revenues (2006-2011) Global Hemophilia A Market Size (2010-2016F) Global Recombinant FVIII Market Revenues (2005-2011) Global Hemophilia B Market Size (2010-2016F) Global Recombinant FIX Market Size (2006-2011) Annual Global Sales of NovoSeven (2007-2011) Quarterly Sales of Novoseven (Q109-Q112) Major Clotting Disorders, by Volume of Patients Requiring Treatment (2010) Demand of Plasma Derived Factor IX in Australia (2007-2010) Demand of Recombinant Factor IX in Australia (2007-2010) The US Plasma Derived FVIII Market Share by Companies (2010) Distribution Growth of rFVIII products in the US (Nov 2010-Nov 2011) Use of Prophylaxis in Different Age Brackets (2011) Global Male Population (2005-2014F) Novo Nordisk Revenue Share by Business Segments (2011) Novo Nordisk Revenues & Net Income (2008-2011) Baxter’s Revenue by Business Segments (2011) Baxter’s Revenues and Net Income (2008-2011) Grifols Revenue Share by Business Segments (2011) Grifols Revenues & Profits (2008-2011) Pfizer’s Revenue Share by Business Segments (2011) Pfizer’s Revenues & Net Income (2008-2011) Global Hemophilia Treatment Market Forecast (2010-2014F)
2.2 Global Hemophilia Market by Type 2.2.1 Hemophilia A Market Characteristics Market Size Key Products 2.2.2 Hemophilia B Market Characteristics Market Size Key Products 2.2.3 Hemophilia with Inhibitor 2.3 Global Hemophilia Therapeutics Market by Region 2.3.1 Australia Market Overview Volume of Patients Demand of Plasma Derived Factor IX Demand of Recombinant Factor IX 2.3.2 The US Market Overview Plasma Derived rFVIII Market Share Distribution Growth of FVIII products New Patient Registrations
3. Hemophilia Market Dynamics 3.1 Key Trends 3.1.1 Inclination towards Prophylaxis 3.1.2 Abated Use of Central Venous Access Device for Prophylactic
List of Tables Market Characteristics for Hemophilia A Treatments (2010) Revenues of Key Products in Hemophilia A Treatment Market (2010 & 2016F) Products for Hemophilia A Treatment Market Characteristics for Hemophilia B Treatments (2010)
View Report Details 3.1.3 Long-Acting Factor VIII and IX Development 3.1.4 Growing Penetration of rFVIII Products in Emerging Markets – Opportunity for Manufacturers 3.2 Industry Developments 3.2.1 Innovative Gene Therapy for Treating Heamophilia B 3.2.2 Extended Half Life of the Recombinant Coagulation Factors 3.2.3 Development of 4-factor PCC for Reversal of Vitamin K Antagonist Anticoagulant Therapy 3.2.4 Approval of ADVATE in China 3.2.5 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A 3.3 Growth Drivers 3.3.1 Increasing New Patient Registration 3.3.2 Rising Male Population 3.3.3 Increasing Expenditure on Healthcare 3.3.4 Increasing Life Expectancy for Hemophilia Patients 3.4 Challenges 3.4.1 Risk of Antibody Neutralization 3.4.2 Misdiagnosis of the Disease 4. Hemophilia Market - Competitive Scenario Competition in Hemophilia A Market Competition in Hemophilia B Market
5. Company Profiles 5.1 Novo Nordisk Business Description Key Financials Business Strategies Focus on Hormone Therapy Establish Leadership Position 5.2 Baxter International Business Description Key Financials
Revenues of Key products in Hemophilia B Treatment Market (2010 & 2016F) Products for Treatment of Hemophilia B New Patient Registrations in the US Bleeding Disorders Market (19982013E) Growth in the New Patient Registrations in the US (2009-2013E) Treatment of Hemophilia B Patients registered at CDC, the US (December 2011) Long Acting FIX & FVIII under Late-Stage Development % Conversion to Recombinant Factor VIII Products in Selected Countries (2010) Reduction in the Number of Injections required by using Half-Life Extension Extended Half Life rFVIII Agents Extended Half Life rFIX Agents New Patient Registrations in Worldwide Bleeding Disorders Market (20082013E) Viral Infection Rates among Hemophiliacs (by Disease Type) Competition in Hemophilia A Market – Emerging Products Competition in Hemophilia B Market – Emerging Products Dependent & Independent Variables (2006-2011) Correlation Matrix Model Summary – Coefficient of Determination Regression Coefficients Output
View Report Details Business Strategies Focus on Investment in Research & Development Achieving Growth through Sustainable Development
5.3 Grifols Business Description Key Financials Business Strategies Expansion in Other Geographic Regions Growth through Mergers & Acquisitions 5.4 Pfizer, Inc. Business Description Key Financials Business Strategies Focus on Growth Strategic Acquisitions 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology 6.2.1 Dependent and Independent Variables 6.2.2 Correlation Analysis 6.2.3 Regression Analysis
View Report Contact Us:Details These are abridged and sanitized sample pages from the comprehensive report on the “Global Hemophilia Market Report : 2012 Edition”. To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta BD Manager
CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com
www.konceptanalytics.com